We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > BYDUREON BCise

News List

FDA Approves Pediatric Type 2 Diabetes Treatment americanpharmaceuticalreview
July 26, 2021
The U.S. FDA approved Bydureon and Bydureon BCise (exenatide extended-release) injection to be used in addition to diet and exercise to improve glycemic control (blood sugar levels) in pediatric patients 10 years or older with type 2 diabetes.
EU approves AZ’ Bydureon BCise device pharmatimes
September 14, 2018
AstraZeneca says the European Commission has approved a new formulation of its once-weekly diabetes drug Bydureon.
European Commission Approves Bydureon BCise Device for Patients with Type-2 Diabetes americanpharmaceuticalreview
August 31, 2018
AstraZeneca announced the European Commission (EC) has approved Bydureon BCise (exenatide 2mg prolonged-release suspension for injection in pre-filled pen) as a new formulation within the marketing authorization for Bydureon (exenatide extended release) f
AstraZeneca's BYDUREON BCise Injectable Medicine Now Available in the U.S. for Patients With Type-2 biospace
January 11, 2018
AstraZeneca today announced that BYDUREON® BCise™ (exenatide extended-release) injectable suspension 2mg is now available in pharmacies across the United States.